Abstract
We review current approaches that can extend our understanding of monogenic disease towards complex disease. Recent studies showed that currently established disease genes differ in their protein size, tissue specificity and the phylogenetic distribution of homologs. These characteristics can be explained by the fact that monogenic disease mutations must be sufficiently deleterious to produce a clearly recognizable phenotype, but also must not be lethal in an early embryonic stage. On the other hand, deletion of each gene in the human genome must be evolutionarily disadvantageous. For most genes, this disadvantage might manifest as an increased susceptibility to complex disease. Accordingly, mildly deleterious variants can be observed in a wide spectrum of genes. The phenotypic manifestation of these mildly deleterious variants might depend on somatic mutations, which cause the breakdown of compensating mechanisms in individual cells. At present, association studies are the most promising strategy for mapping complex disease phenotypes. However, these are restricted to the identification of common disease variants and often provide only marginally convincing statistical evidence. Novel computational strategies, which take prior biological knowledge into account, therefore might play a major role in the design and interpretation of large-scale association studies.
Keywords: human genes, phenotype, genome sequence, HapMap project, genetic variants
Current Genomics
Title: Approaching Inherited Disease on a Genomic Scale
Volume: 6 Issue: 7
Author(s): Jan Freudenberg, Ying-Hui Fu and Louis J. Ptacek
Affiliation:
Keywords: human genes, phenotype, genome sequence, HapMap project, genetic variants
Abstract: We review current approaches that can extend our understanding of monogenic disease towards complex disease. Recent studies showed that currently established disease genes differ in their protein size, tissue specificity and the phylogenetic distribution of homologs. These characteristics can be explained by the fact that monogenic disease mutations must be sufficiently deleterious to produce a clearly recognizable phenotype, but also must not be lethal in an early embryonic stage. On the other hand, deletion of each gene in the human genome must be evolutionarily disadvantageous. For most genes, this disadvantage might manifest as an increased susceptibility to complex disease. Accordingly, mildly deleterious variants can be observed in a wide spectrum of genes. The phenotypic manifestation of these mildly deleterious variants might depend on somatic mutations, which cause the breakdown of compensating mechanisms in individual cells. At present, association studies are the most promising strategy for mapping complex disease phenotypes. However, these are restricted to the identification of common disease variants and often provide only marginally convincing statistical evidence. Novel computational strategies, which take prior biological knowledge into account, therefore might play a major role in the design and interpretation of large-scale association studies.
Export Options
About this article
Cite this article as:
Freudenberg Jan, Fu Ying-Hui and Ptacek J. Louis, Approaching Inherited Disease on a Genomic Scale, Current Genomics 2005; 6 (7) . https://dx.doi.org/10.2174/138920205775067693
DOI https://dx.doi.org/10.2174/138920205775067693 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Local Gene Delivery for Cancer Therapy
Current Gene Therapy Platelets in Alzheimer’s Disease-Associated Cellular Senescence and Inflammation
Current Pharmaceutical Design Mitochondrial Signaling and Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Implications
Current Pharmaceutical Design Management of Incidental Findings in the Era of Next-generation Sequencing
Current Genomics Smad-Signaling in Mammary Gland Development and Tumorigenesis
Current Signal Transduction Therapy Review: Recent Clinical Trials in Epigenetic Therapy
Reviews on Recent Clinical Trials Glycogen Synthase Kinase-3 - An Overview of An Over-Achieving Protein Kinase
Current Drug Targets An Integrated and Disease-Oriented Growth Factor-Regulated Signal Transduction Network
Current Molecular Medicine Protein-Protein Interactions: Lessons Learned
Current Medicinal Chemistry - Anti-Cancer Agents Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry Subject Index To Volume 6
Current Molecular Medicine Recent Developments in the Mechanism of Anticancer Agents Based on Electron Transfer, Reactive Oxygen Species and Oxidative Stress
Anti-Cancer Agents in Medicinal Chemistry Secondary Radiation-Induced Bone Tumours Demonstrate a High Degree of Genomic Instability Predictive of a Poor Prognosis
Current Genomics Mouse Induced Glioma-Initiating Cell Models and Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry High Mobility Group Box 1 Protein as a Potential Drug Target for Infection- and Injury-Elicited Inflammation
Inflammation & Allergy - Drug Targets (Discontinued) Profiling the Shear Stress of Atherosclerosis; A Genomic View
Current Genomics NUPR1 Interacts with p53, Transcriptionally Regulates p21 and Rescues Breast Epithelial Cells from Doxorubicin-Induced Genotoxic Stress
Current Cancer Drug Targets Tetraplex Binding Molecules as Anti-Cancer Agents
Recent Patents on Anti-Cancer Drug Discovery Enediyne Anticancer Antibiotic Lidamycin: Chemistry, Biology and Pharmacology
Anti-Cancer Agents in Medicinal Chemistry Pioglitazone and Cancer: Angel or Demon?
Current Pharmaceutical Design